Heart Attack

The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in HypertensionThe effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria…

3 months ago
Winstrol Steroids: Winstrol Benefits, Winstrol Side Effects, Winstrol Results & Buy Winstrol Pills Alternatives Win-Max By CrazyBulkWinstrol Steroids: Winstrol Benefits, Winstrol Side Effects, Winstrol Results & Buy Winstrol Pills Alternatives Win-Max By CrazyBulk

Winstrol Steroids: Winstrol Benefits, Winstrol Side Effects, Winstrol Results & Buy Winstrol Pills Alternatives Win-Max By CrazyBulk

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- “We’ve got several pro bodybuilding athletes ready and waiting to get to…

3 months ago
Covera Health Launches ‘Protect Her™’ – A Breakthrough AI Solution to Advance Early Detection in Women’s HealthCovera Health Launches ‘Protect Her™’ – A Breakthrough AI Solution to Advance Early Detection in Women’s Health

Covera Health Launches ‘Protect Her™’ – A Breakthrough AI Solution to Advance Early Detection in Women’s Health

New AI-powered platform leverages routine imaging to identify hidden health risks for women as they age, improving quality of life…

3 months ago
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic…

3 months ago
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr…

3 months ago
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

Ozempic® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes and peripheral artery disease (PAD)…

3 months ago
Entera Bio Announces Full Year 2024 Financial Results and Provides Business UpdatesEntera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides…

3 months ago
Marius Pharmaceuticals Strengthens IP Portfolio with New KYZATREX® (testosterone undecanoate) CIII Capsules Formulation PatentMarius Pharmaceuticals Strengthens IP Portfolio with New KYZATREX® (testosterone undecanoate) CIII Capsules Formulation Patent

Marius Pharmaceuticals Strengthens IP Portfolio with New KYZATREX® (testosterone undecanoate) CIII Capsules Formulation Patent

RALEIGH, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone…

3 months ago
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of FibromyalgiaTonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL…

3 months ago
Tren-Max (Crazybulk) safe and legal steroid alternative to Trenbolone Acetate, Dosages Cycles Benefits and Guide to Buying Tren Ace, Tren Steroid For Sale!Tren-Max (Crazybulk) safe and legal steroid alternative to Trenbolone Acetate, Dosages Cycles Benefits and Guide to Buying Tren Ace, Tren Steroid For Sale!

Tren-Max (Crazybulk) safe and legal steroid alternative to Trenbolone Acetate, Dosages Cycles Benefits and Guide to Buying Tren Ace, Tren Steroid For Sale!

NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- “Tren-Max is the safe and legal steroid alternative to Trenbolone Acetate" Our…

3 months ago
Show more Posts
Show previous Posts